D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir
Jennifer F Hoy,Michelle E Gahan,Andrew Carr,Don Smith,Sharon R Lewin,Steven Lodewyk Wesselingh,David A. Cooper +6 more
TL;DR: During the 24-week study, there was no significant change in mtDNA copy numbers in PBMCs in either treatment group, despite improvement in peripheral lipoatrophy among patients whose treatment was switched to abacavir.
Journal ArticleDOI
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
Sharon R Lewin,John M. Murray,Ajantha Solomon,Fiona Wightman,Paul U. Cameron,Damian J F Purcell,John Zaunders,Pat Grey,Mark Bloch,Don Smith,David A. Cooper,Anthony D. Kelleher +11 more
TL;DR: HIV-1 RNA measured 12 weeks after initiation of ARV was the only virologic variable associated with viral rebound after treatment interruption in PHI, and led to improved control of viral replication during structured treatment interruption.
Journal ArticleDOI
A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.
Palanee Ammaranond,John Zaunders,Claudette S. Satchell,David van Bockel,David A. Cooper,Anthony D. Kelleher +5 more
TL;DR: A peptide binding assay confirmed that the R264Q mutant peptide had 30-fold lower binding affinity to HLA-B27 compared to wild type, suggesting that this variant is a likely novel escape mutation in HLA -B27-positive individuals.
Journal ArticleDOI
Syringe HIV seroprevalence and behavioural and demographic characteristics of intravenous drug users in Sydney, Australia, 1987.
Jael Wolk,Alex Wodak,Andrew Morlet,James J. Guinan,Eileen J. Wilson,Julian Gold,David A. Cooper +6 more
TL;DR: The contents of needles and syringes returned by intravenous drug users to two Sydney needle and syringe exchange centres were analysed for HIV antibodies by the enzyme-linked immunosorbent assay (ELISA) Reactive and borderline samples were further tested by the Western blot method.
Journal ArticleDOI
Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine
Brett Tindall,Brett Tindall,S. Forde,Michael W. Ross,David Goldstein,Steven Barker,Steven Barker,David A. Cooper,David A. Cooper +8 more
TL;DR: It is found that the provision of information by written mode alone, or written and verbal modes were both associated with significant increases in knowledge levels and that there was a significant interaction in the degree of change between the two methods, with the written plus verbal method showing the most improvement over time.